(AVNS) Avanos Medical - Ratings and Ratios

Avanos Medical, Inc. (NYSE:AVNS), a medical technology company with a global footprint, specializes in innovative solutions for healthcare. Headquartered in Alpharetta, Georgia, and formerly known as Halyard Health, Inc., the company rebranded in June 2018. Avanos operates across North America, Europe, the Middle East, Africa, Asia Pacific, and Latin America, offering a diverse range of medical devices focused on chronic care and pain management.

Their product portfolio includes digestive health solutions such as Mic-Key enteral feeding tubes, known for their ease of use and patient comfort, and Corpak patient feeding solutions, which offer tailored nutrition delivery. Additionally, NeoMed provides neonatal and pediatric feeding solutions, addressing the specific needs of younger patients. In the pain management sector, Avanos offers non-opioid solutions like ON-Q and ambIT surgical pain pumps, which are designed to reduce post-operative pain without the risks associated with opioids. Game Ready combines cold and compression therapy for recovery, while their interventional pain solutions include Coolief for relieving joint pain and OrthogenRx for knee osteoarthritis treatment using hyaluronic acid injections.

Avanos employs a dual distribution strategy, marketing directly to healthcare providers and facilities while also utilizing third-party distributors to ensure broad reach. Their commitment to innovation is evident in their product lines, which are developed to address unmet clinical needs and improve patient outcomes.

Looking ahead, Avanos Medical is positioned for growth, leveraging its global presence and product innovation. The companys market cap of $711.41M reflects its established position, though the high P/E ratio of 32.94 suggests investor confidence in future growth potential. The forward P/E of 0.00 indicates either limited visibility into future earnings or negative expectations, which could be a risk. The P/B ratio of 0.58 points to undervaluation relative to book value, while a P/S of 1.04 suggests moderate growth pricing. However, the low Ro